Advertisement

Topics

Pneumonia Corporate

13:50 EDT 18th March 2019 | BioPortfolio

Bioharmony Therapeutics, Inc.

Bioharmony Therapeutics, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in-class lysin-based antimicrobial therapeutics for patients with multi-drug resistant Gram-negative bacterial infections. In addition to the Acinetobacter lysin, Bioharmony’s portfolio includes a proprietary line-up of lysins for t...

Tricida, Inc.

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Tricida has successfully...

ART Medical

ART Medical, based out of Israel and Palo Alto, was founded by the CEO Liron Elia in 2009. The company offers a range of products that optimize enteral feeding as well as detect and prevent aspiration pneumonia, VAP and Acute Kidney Injury in intubated patients. The technology has received FDA approval and is now in the final processes of clinical trials. ...

Synspira

Synspira is developing a new class of inhalable glycopolymer-based therapeutics that disrupt mucus accumulation and biofilm invasion, which are key drivers of pulmonary diseases including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and pneumonia. Synspira has an exclusive license from Synedgen to the Glycomics Technology Platform fo...

Affinivax, Inc.

Affinivax is advancing a next generation vaccine technology platform to enable the development of vaccines that provide the highest level of protection against challenging infectious diseases. Backed by an investment from the Bill & Melinda Gates Foundation, and working with world experts in vaccine discovery and development, Affinivax is focused on creati...

Genocea Biosciences

Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. The Company’s proprietary T cell-directed antigen discovery program represents a broad platform with the potential to generate significant novel vaccines for multiple pathogens with high unmet medical need. Genocea is currently developing ...

Affinivax Inc.

Affinivax is advancing a next generation conjugate vaccine technology platform to enable the development of vaccines that provide the highest level of protection against challenging infectious diseases. Backed by an investment from the Bill & Melinda Gates Foundation and working with world experts in vaccine discovery and development, Affinivax is focused ...

Special Phage Services

Few inventions in science and medicine have had such a profound effect on human health as the discovery and subsequent development of antibiotics. Following their introduction during World War II many dreaded infectious diseases such as diphtheria, pneumonia, syphilis, and tuberculosis disappeared almost overnight. However all is not well with the antibiotics story. The bacterial pathogens are f...

Phagenesis Ltd

Phagenesis is developing the first clinically proven treatment for dysphagia, a debilitating and often lethal condition in which the patient’s ability to swallow is damaged. Dysphagia can lead to the inhalation of solids or liquids followed by pneumonia. Sufferers face being fed through a tube indefinitely, reduced life expectancy and quality of life....

Pulmatrix, Inc.

Pulmatrix, Inc., is a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases. Pulmatrix’s lead proprietary therapies, called inhaled cationic airway lining modulators (iCALM™), are a novel approach to prevent and treat acute exacerbations an...

Medical Acoustics, LLC

Medical Acoustics’ mission is to design, develop and market devices employing acoustic technologies for diagnostic and therapeutic medical applications. The Company’s first product, the patented Lung Flute®, is a revolutionary medical device that is expected to play a significant role in the treatment, diagnosis of, and drug development for lung ...

Curetis AG

Curetis AG is a molecular diagnostic company focusing on the development and commercialization of a universal molecular diagnostics solution for easy-to-use, fast and reliable molecular disease testing. Curetis harnesses modern biochemistry and system engineering to automate molecular testing at the point of need, initially for rapid identification of bacteria and antibiotic resistances associ...

Phagenesis

Phagenesis is developing the first clinically proven treatment for dysphagia, a debilitating and often lethal condition in which the patient’s ability to swallow is damaged. Dysphagia can lead to the inhalation of solids or liquids followed by pneumonia. Sufferers may face being fed through a tube indefinitely, reduced life expectancy, and many are tr...

Genocea Biosciences, Inc.

Genocea Biosciences is a vaccine discovery and development company targeting major infectious diseases with high unmet medical needs, in which T cell responses help confer protection. The company’s transformational discovery platform mines the natural immune response across diverse human populations in a way that radically reduces the risk, cost and t...

Gen-Probe Life Sciences Ltd

Gen-Probe Incorporated (NASDAQ: GPRO) is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) used primarily to diagnose human diseases and screen donated human blood. NATs harness the power of biotechnology to detect diseases more rapidly and/or accurately than older testing methods, and have therefore become one of the fast...

Sirna Therapeutics, Inc.

The scientific community considers RNA RNARibonucleic acid. A long chain polymer of genetic material similar to DNA except that it is usually found in a single-stranded form rather than as a double helix, it is made up of the ribo nucleotides A, G, C, and U (instead of T), it is somewhat less resistant to cellular degradation enzymes than DNA, and it functions most often as a transient messenger o...

Pulmonary Reviews

Pulmonary Reviews is a monthly news magazine for physicians who specialize in pulmonary and/or critical care medicine. It provides physicians with information on disorders that affect the lungs and respiratory tract. Articles cover such topics as asthma, ARDS, pneumonia, influenza, sepsis, emphysema, chronic bronchitis, sleep apnea, AIDS, and pulmonary embolic disease. Reports on clinical research...

The Hospital of the University of Pennsylvania

A leader in medicine for more than 240 years, Penn opened its School of Medicine, the nation's first, in 1765. The Hospital of the University of Pennsylvania was established in 1874 as the nation's first teaching hospital.Since its founding days, Penn has expanded medical frontiers by creating some of the nation's earliest programs in areas ranging from dermatology, neurosurgery, ophthalmology and...

Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a commercial-stage biopharmaceutical company marketing two FDA-approved products with its national primary care sales force. ANTARA® (fenofibrate) capsules is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE® (gemifloxacin mesylate) tablets is...

IP&MA, Inc

Since 1996, IP&MA has been assisting health care organizations and related industries prevent infectious and other adverse events. IP&MA's professionals have successfully worked with clients to: Decrease the ventilator associated pneumonia rate in intensive care patients by 29%; providing a cost avoidance of over $160,000 per year. Lower the overall nosocomial infection rate for a long term acut...

Enanta Pharmaceuticals, Inc.

Enanta Phatmaceuticals ARE A RESEARCH AND DEVELOPMENT-FOCUSED BIOTECHNOLOGY COMPANY that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta are discovering and developing novel inhibitors designed for use against the hepatitis C virus, or HCV. These inhibitors include members of the direct acting antivi...

CareInternet.net

The continuing education section hosts subscription courses for physicians, nurses, pharmacists, pharmaceutical representatives, health care professionals and lay persons interested in the various topics. The first modules cover antithrombotic therapy and are available now. CareInternet.net will release new modules for hypertension, heart failure and community-acquired pneumonia (CAP) in the comin...

Arpida Ltd

Arpida was founded in 1997 by Dr Dieter Gillessen, Prof. Bernhard Erni and Dr Ivan Kompis along with Dr André Lamotte from New Medical Technologies (NMT, now HBM BioVentures). Arpida’s mission is to discover, develop and commercialise innovative drugs and provide caregivers with novel therapies to overcome the growing problem of microbial resistance. Arpida uses an integrated multidisciplinary ...

US Bioscience Incorporated

US Bioscience, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for patients with cancer and allied diseases such as AIDS. Currently, three of the Company's products are marketed by US Bioscience and its commercial partners: Ethyol® (amifostine) A selective cytoprotective agent for reduction of toxicities associated with cancer chemotherapy. Hexalen...

Apothogen

IntraBiotics' mission is to combine clinical development with recognized commercial expertise for the development and commercialization of emerging drugs and commercial products. To achieve that mission, we strive to deliver medical benefits to patients, to offer professional challenges for employees and to provide competitive returns for investors.Key strategies include: Focus on the de...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Pneumonia market research data and corporate reports here